With more than 20 clinical studies ongoing, Bavarian Nordic A/S has reported a further strengthening of its cash position, largely due to a new licensing and equity agreement with Janssen Pharmaceuticals Inc which raises the US company’s stake in the Danish company to 5.8%.
